Standard triple therapy for Helicobacter pylori infection in China: A meta-analysis

Table 2 Results of meta-analysis

Meta-analyses/subgroup analyses	Eradication rate with control group	RR (95%CI)	I2
Standard triple therapy vs dual therapy	78.00%	1.140 (0.992–1.310)	62.596%
7-d subgroup	73.08%	1.221 (1.084 –1.374)	0.000%
Adverse events		0.651 (0.276–1.539)	0.000%
Standard triple therapy vs sequential therapy	84.00%	0.863 (0.824–0.904)	37.400%
Adult subgroup	82.90%	0.899 (0.861–0.939)	25.942%
Child subgroup	87.29%	0.779 (0.722–0.840)	0.000%
7-d subgroup	87.52%	0.800 (0.752–0.851)	0.000%
10-d subgroup	80.17%	0.849 (0.789–0.913)	42.355%
14-d subgroup	89.72%	0.980 (0.916–1.048)	0.000%
Omeprazole subgroup	87.37%	0.832 (0.772–0.898)	47.049%
Esomeprazole subgroup	77.01%	0.932 (0.871–0.998)	40.061%
Pantoprazole subgroup	87.13%	0.846 (0.746–0.960)	0.000%
Rabeprazole subgroup	91.24%	0.847 (0.766–0.936)	41.871%
Tinidazole subgroup	81.43%	0.889 (0.837–0.944)	38.688%
Metronidazole subgroup	83.20%	0.810 (0.745–0.882)	43.630%
Adverse events		1.176 (0.975–1.419)	0.000%
Standard triple therapy vs quadruple therapy	64.90%	1.073 (0.849–1.357)	93.204%
1-d subgroup	28.42%	2.367 (1.923–2.914)	0.000%
3-d subgroup	66.67%	1.288 (1.061–1.562)	100.000%
7-d subgroup	86.79%	0.790 (0.718–0.868)	0.000%
10-d subgroup	88.04%	0.917 (0.839–1.002)	22.259%
Omeprazole subgroup	66.67%	1.250 (1.012–1.545)	100.000%
Esomeprazole subgroup	73.76%	1.098 (0.699–1.725)	88.852%
Lansoprazole subgroup	45.00%	1.391 (0.404–4.790)	98.719%
Rabeprazole subgroup	83.99%	0.948 (0.771–1.166)	84.733%
Adverse events		0.940 (0.825–1.072)	0.000%
Standard triple therapy with other triple therapies	79.90%	1.010 (0.936–1.089)	72.233%
Adult subgroup	80.92%	0.999 (0.925–1.078)	69.085%
Child subgroup	73.25%	1.079 (0.748–1.557)	74.810%
7-d subgroup	80.32%	1.022 (0.949–1.100)	60.674%
10-d subgroup	77.78%	0.933 (0.821–1.060)	0.000%
14-d subgroup	78.40%	1.050 (0.712–1.549)	93.921%
Omeprazole subgroup	80.30%	1.048 (0.976–1.125)	49.506%
Esomeprazole subgroup	84.47%	0.911 (0.831–0.999)	0.000%
Levofloxacin subgroup	82.37%	0.917 (0.852–0.987)	0.000%
Furazolidone subgroup	85.22%	0.963 (0.762–1.216)	73.898%
Metronidazole subgroup	68.84%	1.119 (0.882–1.420)	80.863%
Adverse events		1.081 (0.848–1.378)	0.000%
Eradication rate with standard triple therapy		74.5%